LAPATINIB IN HER2 POSITIVE METASTATIC CARCINOMA BREAST

被引：0
|
作者：
Behera, M. K. [1 ]
Sharma, A. [1 ]
Shukla, P. [1 ]
Julka, P. K. [1 ]
Rath, G. K. [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
129P
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [1] A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Rooney, Anthony
    Sharma, Priyanka
    O'Dea, Anne P.
    Nye, Lauren
    Elia, Manana
    He, Jianghua
    Fabian, Carol
    Khan, Qamar
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [2] Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Barr, J. A.
    Sharma, P.
    Fabian, C. J.
    Yeh, H.
    Baccaray, S.
    Springer, M.
    Khan, Q. J.
    [J]. CANCER RESEARCH, 2016, 76
  • [3] Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
    O'Connor, Tracey
    Soto-Perez-de-Celis, Enrique
    Blanchard, Suzette
    Chapman, Andrew
    Kimmick, Gretchen
    Muss, Hyman
    Luu, Thehang
    Waisman, James R.
    Li, Daneng
    Mortimer, Joanne
    Yuan, Yuan
    Somlo, George
    Stewart, Daphne
    Katheria, Vani
    Levi, Abrahm
    Hurria, Arti
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [4] Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
    Mathew, S. P.
    Avaronnan, M.
    Shenoy, P. K.
    Devi R, N.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1439 - S1439
  • [5] HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515).
    Lin, N. U.
    Danso, M. A.
    David, A. K.
    Muscato, J. J.
    Ellis, C. E.
    Lahiri, S.
    Sessa, T.
    Nagarwala, Y. M.
    Winer, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Synergistic inhibition of HER2 positive breast cancer by triptolide and lapatinib
    Chalugun, P.
    Shim, J. S.
    Korangath, P.
    Sukumar, S.
    Liu, J. O.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 36 - 36
  • [7] Synergistic inhibition of HER2 positive breast cancer by triptolide and lapatinib
    Chalugun, Paweena
    Shim, Joong Sup
    Korangath, Preethi C.
    Sukumar, Saraswati
    Liu, Jun O.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [8] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
    Jia, W.
    Wang, T. Z.
    [J]. JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555
  • [9] Lapatinib reverses endocrine resistance in select patients with HER2 negative, hormone positive metastatic breast cancer
    Sharma, P.
    Kimler, B. F.
    Ward, C.
    Wang, K.
    Ali, S.
    Balasubramanian, S.
    O'Dea, A. P.
    Madhusudhana, S.
    Baccaray, S.
    Fabian, C. J.
    Schmitt, S. B.
    Godwin, A. K.
    Khan, Q. J.
    [J]. CANCER RESEARCH, 2016, 76
  • [10] A phase I/II study of the combination of lapatinib and oral vinorelbine in HER2 positive metastatic breast cancer
    Chen, T. W-W
    Yeh, D-C
    Chao, T-Y
    Lin, C-H
    Chow, L. W-C
    Hsieh, Y-Y
    Huang, S-M
    Cheng, A-L
    Huang, C-S
    Lu, Y-S
    [J]. CANCER RESEARCH, 2016, 76
12345